Ethical issues of pharmacogenetics must be addressed, says Nuffield CouncilBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7417.701-a (Published 25 September 2003) Cite this as: BMJ 2003;327:701
- Debashis Singh
Pharmacogenetics–the study of how genetic variation affects a patient's response to drugs–holds the promise of safe and effective treatments in the future. But scientists must address ethical and policy issues of this technology if the potential benefits are to be realised. That is the message from the Nuffield Council on Bioethics in a report published this week.
Many drug companies are hopeful that this new technology will lead to the development of “the right medicine, for the right patient, at the right dose.” …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial